MAZE Maze Therapeutics, Inc.

QT46

Latest market price

32.25

+1.88+6.19%

Overview Short InterestFilings

MAZEQT46Maze Therapeutics, Inc.·NASDAQ

Overview Short InterestFilings

32.25+6.19%

Earnings

Up 6.2% — Earnings due 2026-11-05 — pre-report positioning.

Medium confidence

Loading chart...

Signal & projected range

Insider open-market saleHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

URGN+0.12%$34.40 GENB+4.84%$13.85 STOK+1.93%$26.99 ABSI+3.20%$10.00 SLS+3.74%$8.87 NTLA+1.72%$11.86 TRAX+2.86%$46.34 NUVB+2.18%$4.69

Snapshot

Index	—	P/E	—	EPS (ttm)	-2.74	Insider Own	13.72%	Shs Outstand	55.55M	Perf Week	1.77%

Market Cap	1.69B	Forward P/E	—	EPS next Y	-3.21	Insider Trans	-5.22%	Shs Float	16.04M	Perf Month	22.02%

Enterprise Value	1.33B	PEG	—	EPS next Q	-0.76			Short Float	46.94%	Perf Quarter	15.97%

Income	-134.00M	P/S	84.35	EPS this Y	—			Short Ratio	12.79	Perf Half Y	21.42%

Sales	20.00M	P/B	3.72	EPS next Y	—	ROA	-25.13%	Short Interest	7.53M	Perf YTD	-22.16%

Book/sh	8.15	P/C	4.10	EPS next 5Y	—	ROE	-34.94%	52W High	53.65 -39.89%	Perf Year	-2.01%

Cash/sh	7.40	P/FCF	—	EPS past 3/5Y	—	ROIC	-28.35%	52W Low	21.95 46.92%	Perf 3Y	—

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	95.28%	Volatility	4.98% 5.42%	Perf 5Y	—

Dividend TTM	—	EV/Sales	66.60	EPS Y/Y TTM	—	Oper. Margin	-728.06%	ATR (14)	1.63	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	18.31	Sales Y/Y TTM	566.67%	Profit Margin	-667.95%	RSI (14)	63.61	Recom	1.88

Dividend Gr. 3/5Y	—	Current Ratio	18.31	EPS Q/Q	1.30%	SMA20	8.76%	Beta	0.78	Target Price	75.00

Payout	0.00%	Debt/Eq	0.12	Sales Q/Q	—	SMA50	17.00%	Rel Volume	0.73	Prev Close	30.37

Employees	141	LT Debt/Eq	0.12	Earnings	Nov 05	SMA200	1.54%	Avg Volume	671.70K	Price	32.25

IPO Date	Jan 31, 2025	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.95% —	Net Debt/EBITDA	—	Volume	488,818	Change	6.19%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-19-26	Initiated	Canaccord	Buy	$75
Apr-14-26	Reiterated	Truist Securities	Buy	$68 → $64
Mar-17-26	Reiterated	Truist Financial		$68
Mar-10-26	Initiated	Mizuho	Outperform	$97
Jan-16-26	Reiterated	BTIG	Buy	$30 → $46
Dec-19-25	Reiterated	Guggenheim	Buy	$34 → $46
Dec-04-25	Initiated	Wells Fargo	Overweight	$55
Dec-03-25	Reiterated	HC Wainwright & Co.	Buy	$60
Nov-13-25	Initiated	Raymond James	Strong Buy	$48
Sep-15-25	Reiterated	Guggenheim	Buy	$34

Latest News· Times ET

Today

Today07:00AM

Maze Therapeutics to Participate in Upcoming Investor Conferencesglobenewswire.com

Oct-19-26

Oct-19-2601:01PM

What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stockzacks.com

10:55AM

How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%zacks.com

10:12AM

Here Are Monday’s Top Wall Street Analyst Research Calls: Ameriprise Financial, Boyd Gaming, CoreWeave, Datadog, Intel, JetBlue Airways, PayPal Holdings, Pinterest, Whirlpool, and More247wallst.com

09:37AM

Intel upgraded, Reddit initiated: Wall Street's top analyst callsYahoo

Oct-16-26

Oct-16-2602:59AM

Maze Therapeutics (NASDAQ:MAZE) vs. Nektar Therapeutics (NASDAQ:NKTR) Financial Analysisdefenseworld.net

Oct-13-26

Oct-13-2610:31AM

Pompe Disease Market Set for Expansion During the Forecast Period (2026-2036) as Growth is Fueled by Next-Generation ERTs, Newborn Screening, and Pipeline Innovation | DelveInsightYahoo

06:15AM

Head to Head Survey: Maze Therapeutics (NASDAQ:MAZE) and Cytokinetics (NASDAQ:CYTK)defenseworld.net

Oct-06-26

Oct-06-2604:05PM

Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026globenewswire.com

Oct-05-26

Oct-05-2610:55AM

3 Small-Cap Stocks With Catalysts That Could Put Them in the Spotlightmarketbeat.com

Oct-01-26

Oct-01-2604:15AM

Maze Therapeutics, Inc. (NASDAQ:MAZE) Stock Has Consensus Price Target of $63.40defenseworld.net

Sep-30-26

Sep-30-2606:41AM

Maze Therapeutics (NASDAQ:MAZE) Shares Climb 4.5% – Still a Buy?defenseworld.net

Sep-28-26

Sep-28-2608:37PM

Could Vertex Pharmaceuticals (VRTX)’s Kidney Breakthrough Unlock a New Opportunity for Maze Therapeutics (MAZE)?Yahoo

Sep-24-26

Sep-24-2604:41AM

Maze Therapeutics (NASDAQ:MAZE) Shares Gap Up – Time to Buy?defenseworld.net

Sep-22-26

Sep-22-2610:30AM

Gapping stocks in Tuesday's sessionChartMill

Company

Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022
Total Revenue	20	0	168	0	—
Cost of Goods Sold Incl. D&A	0	2	0	0	—
Gross Profit	20	-2	168	0	—
Selling, General and Administrative Excl. Other	43	34	26	25	—
Research and Development	122	108	83	74	—
Other Operating Expense	0	-2	1	0	—
Operating Income	-146	-143	58	-99	—
Interest Expense	2	0	0	0	—
Unusual Expense	—	—	—	—	—
Non-Operating Income (Expense)	13	12	-4	-2	—
Net Income Before Taxes	-134	-131	53	-100	—
Income Taxes	0	0	1	0	—
Consolidated Net Income	-134	-131	52	-100	—
Net Income From Continuing Operations	-134	-131	52	-100	—
Net Income	-134	-131	52	-100	—
EPS (Recurring)	-2.74	-3.05	0.08	-2.29	—
EPS (Basic, Before Extraordinaries)	-2.74	-3.05	0.08	-2.29	—
EPS (Diluted)	-2.74	-3.05	0.08	-2.29	—
EBITDA	-130	-129	57	-96	—
Other After Tax Adjustments	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—
Price To Sales Ratio	95.14	—	—	—	—
Gross Margin	100.00	—	100.00	—	—
Operating Margin	-730.00	—	34.52	—	—
Net Margin	-670.00	—	30.95	—	—
Shares Outstanding	59	43	44	44	—
Market Capitalization	1,903	1,781	—	—	—
Operating Lease Expense	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dandekar Atul	CSBO	Oct 29 '26	Option Exercise	10.42	7,500	78,150	39,816	Oct 30
Dandekar Atul	CSBO	Oct 29 '26	Sale	32.07	7,500	240,532	32,316	Oct 30
Bernstein Harold	President, R&D & CMO	Oct 01 '26	Sale	26.93	16,141	434,743	0	Oct 02
Bernstein Harold	President, R&D & CMO	Oct 01 '26	Option Exercise	10.42	16,141	168,189	16,141	Oct 02
Coloma Jason V	Chief Executive Officer	Oct 01 '26	Sale	27.02	34,501	932,259	15,558	Oct 02
Dandekar Atul	CSBO	Sep 29 '26	Option Exercise	10.42	7,500	78,150	39,816	Oct 01
Dandekar Atul	CSBO	Sep 29 '26	Sale	27.06	7,500	202,921	32,316	Oct 01
Bernstein Harold	President, R&D & CMO	Sep 04 '26	Sale	26.22	9,705	254,502	0	Sep 08
Bernstein Harold	President, R&D & CMO	Sep 03 '26	Sale	26.01	5,189	134,969	9,705	Sep 04
Courtney Phillips	GC and Corp. Secretary	Sep 03 '26	Sale	26.01	2,012	52,333	7,007	Sep 04
Dandekar Atul	CSBO	Sep 03 '26	Sale	26.01	3,243	84,354	32,316	Sep 04
Coloma Jason V	Chief Executive Officer	Sep 03 '26	Sale	26.01	11,411	296,807	27,362	Sep 04
Coloma Jason V	Chief Executive Officer	Sep 02 '26	Sale	26.47	11,227	297,148	38,773	Sep 04
Courtney Phillips	GC and Corp. Secretary	Sep 02 '26	Sale	26.47	1,981	52,431	9,019	Sep 04
Bernstein Harold	President, R&D & CMO	Sep 02 '26	Sale	26.47	5,106	135,142	14,894	Sep 04

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.